Medicure Inc.’s (MPH.V) (MCUJF.OB) supplemental New Drug Application for Aggrastat to include the treatment of patients presenting with ST segment elevation myocardial infarction (*STEMI) intended for percutaneous coronary intervention is under FDA review – with a decision slated for July 10, 2016.Aggrastat is already approved by the FDA to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. The annual net revenue from the sale of Aggrastat finished product was $22.1 million in 2015, up from $8.4 million in 2014.If approved for STEMI, Aggrastat would be the first in its class of Glycoprotein IIb/IIIa Inhibitors (GPI) to receive such a label in the United States.* A STEMI is the most serious type of heart attack.